Factors Associated with Decision Making in the Second-Line Treatment of Patients with Advanced/Metastatic Gastrointestinal Cancers
This enduring educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The program aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers, and to select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.
RELEASED DATE: October 13, 2023
EXPIRATION DATE: November 28, 2024